GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...

The Advisory Committee on Immunization Practices (ACIP) recommends a single dose of zoster vaccine for immunocompetent adults 60 years of age and older, based on the results of this study ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

The latest research suggests that the recombinant shingles vaccine may offer additional benefits. It appears to reduce the ...

PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...

Aussies who are classified as 'moderate to high risk' and are aged between 18 and 64 now qualify for the immunisation.

Shingrix is approved to prevent shingles (herpes zoster) in adults aged 50 and older ... Also Read: GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like ...

Mpox transmits through close physical contact, including sexual contact. There is no evidence that it spreads easily through ...